Do we need new CT dose reference levels in pandemics? In 1,600 COVID-19 patients, chest CT doses varied 5-fold across hospitals, affecting dose and cancer risk. These data support pandemic-specific DRLs. https://t.co/nhprKeUmDC #CT #RadiationDose #DRL #MedicalPhysics #Radiology

@JVIRmedia Thank you for publishing our work. We’d be grateful if you could share it with your audience.

A novel IR solution for refractory ureteral occlusion The double guidewire loop technique enables percutaneous neoureterocystostomy when surgery or cystoscopy fails—effective, surgery-sparing https://t.co/1b0fzCwgg6 #InterventionalRadiology #IRTwitter #Fluoroscopy #Urology #JVIR

@FrontiersIn Thank you for publishing our work. We’d be grateful if you could share it with your audience.

Thyroid involvement on non-contrast chest CT correlates with lung severity and survival in COVID-19. Simple CT findings may support clinical risk stratification. https://t.co/omXRfaeDnG #COVID19 #Radiology #CT #Endocrinology #Thyroid

CT-based body composition tells a clear story: Lower muscle volume/body ratio → worse COVID-19 outcomes Simple, routine CT metrics can support early risk stratification. https://t.co/JeI9GSksiV #COVID19 #CT #Radiology #Sarcopenia #Imaging

@BioMedCentral Thank you for publishing our work. We’d be grateful if you could share it with your audience.

@JournalAnd96353 Thank you for publishing our work. We’d appreciate a share with your audience.

@Tomography_MDPI Thank you for publishing our work. We’d be grateful if you could share it with your audience.

@JCM_MDPI Thank you for publishing our work. We’d appreciate it if you could share it with your audience.

@JClinMed_mdpi Thanks for publishing our work. We’d appreciate a share with your audience.

CT muscle loss predicts COVID-19 death — fat doesn’t. https://t.co/JeI9GSksiV #COVID19 #Radiology #CT #Sarcopenia #MedTwitter

Takeaway: Pituitary microadenomas rarely grow and are often visible without contrast. Annual gadolinium is usually unnecessary in stable cases. Full paper (open access): https://t.co/H67N74Ecjl #MRI #Pituitary #Radiology #MedTwitter

Our data support a shift: Non-contrast T1/T2 often enough for follow-up Contrast only for unclear or changing cases → Less gadolinium, same care quality. 🔗

Gadolinium improves visibility — but adds cost, time, retention concerns, and offers no management benefit in stable microadenomas. So do we really need yearly contrast? https://t.co/H67N74Ecjl

Most microadenomas were completely stable. Even in patients with 5+ years of imaging follow-up, there was no meaningful growth and no clinically relevant enlargement on serial MRI. This suggests that aggressive imaging protocols may not match real-world tumor biology.

Contrast-enhanced T1 had the highest detection rate (88.6%), but non-contrast sequences still detected a significant proportion (70.9% on T2W, 65.5% on T1W). Key question: if tumors aren’t growing, why do we perform routine contrast every year?

Are we overusing gadolinium in pituitary microadenoma follow-up? Our new study analyzing 300 MRIs shows that most microadenomas stay radiologically silent for years—and many are already detectable without contrast. https://t.co/H67N74Ecjl

Depression in RRMS has measurable MRI correlates—especially in limbic and insular regions—even in early, low-disability disease. Full article: https://t.co/r8VfwI0yIO #MSResearch #Neuroimaging #Radiology #MentalHealthAwareness

BDI scores correlated with lesion load in mood networks: Left insular cortex: r = 0.20 Total insular cortex: r = 0.19 Even small disruptions in these hubs influence emotional symptoms. https://t.co/r8VfwI00Tg